Scientific breakthroughs and impactful progression of new technological advancements have created new hope for oncology patients, with precision medicine enabling very targeted therapies and further supported by patient centric drug delivery technologies such as single or multi-use devices and wearable technologies, freeing patients from the burdens of in-clinic administration.
Date: Tuesday 10th June, 13:00
Venue: Basel Marriott Hotel, Messepl. 25, 4058 Basel, Switzerland
Join us with Ypsomed, Worldwide Clinical Trials and ProBioGen for an informative session on the rapidly advancing frontier of new oncology pathways such as Antibody Drug Conjugates (ADC’s), oligonucleotides, radiopharmaceuticals, advanced biologics, and other rapidly advancing sciences, coupled with innovative new drug-device combination technologies, with example technologies at the forefront of breakthrough science. We will discuss the impact of these new medicines as we consider new paradigms for manufacturing and supply chain fulfillment in support of oncology patients around the world.
13:00 - Registration
14:00 - Welcome & introduction
14:15 - Breakthrough Science in Oncology: Engendering Hope
Matt Cooper, PhD. Executive Director | Therapeutic Strategy Lead, Oncology. WorldWide Clinical Trials
15:00 - The impact of new therapeutic pathways on drug substance and drug product manufacturing & supply chains
Ron Chan, Business Development Executive, PCI Pharma Services & Michiel Stork, VP Business Development, ProBioGen
15:45 - How oncology breakthroughs are impacting clinical trial execution and logistics
16:30 - Transforming the patient experience: Innovations to provide safe and effective self-administration
Justin Schroeder – Global Vice President, Technical Sales, PCI Pharma Services &
Ralf Kuenzi – Account & Business Development Manager, YPSOMED
17:15 - Drinks reception & buffet dinner
For full event agenda and registration, please Click Here.